Table 1 Baseline characteristics of the entire cohort and propensity-matched sample
Entire cohort | Propensity-matched sample | |||||
|---|---|---|---|---|---|---|
Non-Eos | Eos | Non-Eos | Eos | |||
(n = 1176) | (n = 156) | P-value | (n = 156) | (n = 156) | P-value | |
Clinical | ||||||
Age,yrs | 64[53, 74] | 65[54, 76] | 0.278 | 63[50, 73] | 65[54, 76] | 0.161 |
Male | 522 (44.4) | 82 (52.6) | 0.054 | 68 (43.6) | 82 (52.6) | 0.113 |
Years | 0.372 | 0.0002* | ||||
2012–2014 | 373(31.7) | 55(35.3) | 31(19.9) | 55(35.3) | ||
2015–2017 | 414(35.2) | 58(37.8) | 48(30.8) | 58(37.8) | ||
2018–2020 | 389(33.1) | 43(26.9) | 77(49.4) | 43(26.9) | ||
Comorbidities | ||||||
Asthma | 59(5.0) | 15(9.6) | 0.018* | 16(10.3) | 15(9.6) | 0.850 |
COPD | 150(12.8) | 32(20.5) | 0.008* | 25(16.0) | 32(20.5) | 0.305 |
Diabetes mellitus | 116(9.9) | 18(11.5) | 0.514 | 25(16.0) | 18(11.5) | 0.250 |
Pulmonary tuberculosis | 134(11.4) | 29(18.6) | 0.010* | 31(19.9) | 29(18.6) | 0.774 |
Hematological malignancy | 11(0.9) | 2(1.3) | 0.679 | 3(1.9) | 2(1.3) | 0.652 |
Connective tissue disease | 52(4.4) | 3(1.9) | 0.122 | 2(1.3) | 3(1.9) | 0.652 |
Renal disease | 52(4.4) | 10(6.4) | 0.268 | 10(6.4) | 10(6.4) | 1.000 |
Congential immunodeficiency | 4(0.3) | 1(0.6) | 0.564 | 0 (0) | 1(0.6) | 0.317 |
Solid tumor | 144(12.2) | 14(9.0) | 0.235 | 10(6.4) | 14(9.0) | 0.395 |
Cardiovascular disease | 510(43.4) | 73(46.8) | 0.417 | 63(40.4) | 73(46.8) | 0.254 |